CG Oncology, Inc. Common stock

CGON XNAS • BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

6.1B

Short interest (Jul 15)

13.7%

Net Short (Jul 27 ): 0.1%

Borrow Fee

0.25%

Available Shares

300K

Price Chart

Company Overview

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Company Info

Exchange: NASDAQ

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

CIK: 0001991792

Asset Type: CS

Market Data

Market Cap: $6,114,195,428

Employees: 142

Status: Active

Short Interest

Current Borrow Fee 0.25%

Range: 0.25% - 0.25%

Available Shares 300K

Range: 200K - 300K

Recent Changes

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime